{"id":"W3087179831","doi":"10.1182/blood.2020006578","title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"Cilag; Janssen Pharmaceuticals; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Servier; Juno Therapeutics; Eisai; TG Therapeutics; H. Lundbeck A/S; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Kite Pharma; Unum Therapeutics; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen","keywords":"Venetoclax; International Prognostic Index; Medicine; Internal medicine; Diffuse large B-cell lymphoma; Rituximab; Vincristine; CHOP; Prednisone; Hazard ratio; Population; Tolerability; Oncology; Cyclophosphamide; Lymphoma; Gastroenterology; Adverse effect; Confidence interval; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405243,0.001101592,0.001128727,0.0004109214,0.0002687789,0.0006007255,0.0007043433,0.0008930448,0.003381452],"category_scores_gemma":[0.000831712,0.000498581,0.0007480362,0.0003301984,0.0005859578,0.0005387887,0.0002416949,0.002198469,0.0006618809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006986744,"about_ca_system_score_gemma":0.001136082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009641842,"about_ca_topic_score_gemma":0.003188986,"domain_scores_codex":[0.9997024,0.0001674521,0.000009689903,0.00004778717,0.00002619967,0.00004643708],"domain_scores_gemma":[0.9996141,0.00008086678,0.00007809964,0.00003287319,0.00002611237,0.0001680656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7026074,0.1057607,0.008178655,0.0009745275,0.0009589989,0.0003299044,0.0003254656,0.002285276,0.03822574,0.0004788942,0.005848614,0.1340258],"study_design_scores_gemma":[0.6679305,0.3160855,0.009619455,0.00003080314,0.0002268897,0.0002772566,0.00003563804,0.001055603,0.001783769,0.0001632197,0.002770108,0.00002114446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879798,0.002322418,0.0006908213,0.0004142013,0.0001383465,0.004553289,0.001283384,0.0001541952,0.002463677],"genre_scores_gemma":[0.9817546,0.00210356,0.003433256,0.0009924739,0.0002206009,0.004602703,0.003058703,0.00003919387,0.003794875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003381452,"threshold_uncertainty_score":0.01131213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01977755846897808,"score_gpt":0.2736588602511703,"score_spread":0.2538813017821921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}